Evotec and Centogene Expand their Collaboration to Target Gaucher Disease


  • The two companies will work together to research, discover, and develop therapeutic options related to the deficiency of the protein GBA which is a gene linked to Gaucher disease
  • The collaboration will combine Evotec’s iPSC platform and drug discovery and development capabilities with Centogene’s global rare disease platform, including iPSC lines
  • The collaboration follows the companies 2018 agreement to discover and develop novel small molecules in rare hereditary metabolic diseases

Click here ­to­ read full press release/ article | Ref: Evotec | Image: Wikipedia